TGTX
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
Article Summary
BUY- TG Therapeutics Inc. (NASDAQ: TGTX) announced completion of enrollment in Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), TG Therapeutics's anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS), with top-line data expected year-end 2026/ first quarter 2027.
- The trial is a randomized, open label, parallel-group, multicenter multicenter study designed to evaluate pharmacokinetics, pharmacodynamics, safety, radiological and clinical effects of sub cutaneous BriUMVI compared to IV BRI UMVI in adult participants with RMS, with the primary endpoint of the trial being non inferior exposure of subcut's versus IV exposure with respect to area under the curve (AUC) at week 24.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 87.3% | 25% | 100.0 ptsExceptional (87.3%) - Hypergrowth |
| EPS Growth Next 5Y ? | 0.9% | 25% | 10.0 ptsVery Weak (0.9%) - Minimal expectations |
| Target Price Upside ? | 28.3% | 20% | 75.0 ptsSignificant Upside (28.3%) - Target: $44.43 vs Current: $34.62 |
| Gross Margin % ? | 83.7% | 15% | 100.0 ptsExceptional (83.7%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -25.5% | 15% | 80.0 ptsSolid Dip (-25.5%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About TGTX
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
- The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
- The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
- Its research pipeline includes various investigational medicines.
- The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co.
- Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.